Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

UCB adds website for its Facebook-based Parkinson’s community

Says the site forms the next chapter for More than Motion

- PMLiVE

Amgen sues Sanofi and Regeneron over eczema drug

Alleges patent infringement and seeks financial reparations

- PMLiVE

Amgen wins European approval for Humira biosimilar Amgevita

European Commission approves the first version of AbbVie's blockbuster

- PMLiVE

Repatha outcomes data “less than stellar”

Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements

- PMLiVE

NICE set to back Parsabiv for kidney disease complication

Draft guidance recommends Amgen treatment for secondary hyperparathyroidism

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Hopes ENDEAVOR trial results will give it an edge over Takeda's brand

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

- PMLiVE

Amgen’s chronic kidney disease drug Parsabiv cleared in US

Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years

- PMLiVE

New outcomes data could unlock Repatha’s potential, says Amgen

Evidence of significant cardiovascular benefit could boost slow sales for projected blockbuster

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links